UB Paderborn / Katalog / Suche / in CDI

Short- and Longterm Glycemic Control of Streptozotocin-Induced Diabetic Rats Using Different Insulin Preparations

PloS one, 2016-06, Vol.11 (6), p.e0156346-e0156346

2016

Volltextzugriff (PDF)

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics

mAbs, 2023-12, Vol.15 (1), p.2191301-2191301

2023

Volltextzugriff (PDF)

Characterization of Micro-RNA Changes during the Progression of Type 2 Diabetes in Zucker Diabetic Fatty Rats

International journal of molecular sciences, 2016-05, Vol.17 (5), p.665-665

2016

Volltextzugriff (PDF)

Discovery and translation of a target engagement marker for AMP-activated protein kinase (AMPK)

PloS one, 2018-05, Vol.13 (5), p.e0197849-e0197849

2018

Volltextzugriff (PDF)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

ESC Heart Failure, 2021-08, Vol.8 (4), p.2580-2590

2021

Volltextzugriff (PDF)

A reference map of potential determinants for the human serum metabolome

Nature (London), 2020-12, Vol.588 (7836), p.135-140

2020

Volltextzugriff (PDF)

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3004-3004

2022

Volltextzugriff (PDF)

Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis

Advances in therapy, 2024, Vol.41 (1), p.364-378

2024

Volltextzugriff (PDF)

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Nature biotechnology, 2023-03, Vol.41 (3), p.399-408

2023

Volltextzugriff (PDF)

Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter

FEBS letters, 2012-02, Vol.586 (3), p.248-253

2012

Volltextzugriff (PDF)

A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3016-3016

2021

Volltextzugriff (PDF)

Abstract C047: A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C047-C047

2019

Volltextzugriff (PDF)

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3660-TPS3660

2020

Volltextzugriff (PDF)

Normalization of Prandial Blood Glucose and Improvement of Glucose Tolerance by Liver-Specific Inhibition of SH2 Domain–Containing Inositol Phosphatase 2 (SHIP2) in Diabetic KKAy Mice

Diabetes (New York, N.Y.), 2007-09, Vol.56 (9), p.2235-2241

2007

Volltextzugriff (PDF)

Author Correction: Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Nature biotechnology, 2023-07, Vol.41 (7), p.1026-1026

2023

Volltextzugriff (PDF)

89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

European journal of nuclear medicine and molecular imaging, 2023-06, Vol.50 (7), p.2068-2080

2023

Volltextzugriff (PDF)

Abstract LB003: BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB003-LB003

2023

Volltextzugriff (PDF)

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Diabetes, metabolic syndrome and obesity, 2014-01, Vol.7 (default), p.265-275

2014

Volltextzugriff (PDF)

89 Zr-immuno-PET using the anti-LAG-3 tracer [ 89 Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

European journal of nuclear medicine and molecular imaging, 2023-06, Vol.50 (7), p.2068

2023

Volltextzugriff (PDF)

Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation

FEBS letters, 2007-12, Vol.581 (30), p.5885-5890

2007

Volltextzugriff (PDF)

Phorbol ester-induced activation of mitogen-activated protein kinase/extracellular-signal-regulated kinase kinase and extracellular-signal-regulated protein kinase decreases glucose-6-phosphatase gene expression

Biochemical journal, 2001-08, Vol.357 (3), p.867-873

2001

Volltextzugriff (PDF)

Fingerprints of hSGLT5 sugar and cation selectivity

American Journal of Physiology: Cell Physiology, 2014-05, Vol.306 (9), p.C864-C870

2014

Volltextzugriff (PDF)

Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes

Biochemical journal, 2008-06, Vol.412 (2), p.359-366

2008

Volltextzugriff (PDF)

Normalization of Prandial Blood Glucose and Improvement of Glucose Tolerance by Liver-Specific Inhibition of SH2 Domain-Containing Inositol Phosphatase 2 (SHIP2) in Diabetic KKA^sup y^ Mice: SHIP2 Inhibition Causes Insulin-Mimetic Effects on Glycogen Metabolism, Gluconeogenesis, and Glycolysis

Diabetes (New York, N.Y.), 2007-09, Vol.56 (9), p.2235

2007

Volltextzugriff (PDF)

Tumour necrosis factor α decreases glucose-6-phosphatase gene expression by activation of nuclear factor κB

Biochemical journal, 2004-09, Vol.382 (2), p.471-479

2004

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Short- and Longterm Glycemic Control of Streptozotocin-Induced Diabetic Rats Using Different Insulin Preparations

Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics

Characterization of Micro-RNA Changes during the Progression of Type 2 Diabetes in Zucker Diabetic Fatty Rats

Discovery and translation of a target engagement marker for AMP-activated protein kinase (AMPK)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure

A reference map of potential determinants for the human serum metabolome

A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS)

Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter

A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors

Abstract C047: A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors

Normalization of Prandial Blood Glucose and Improvement of Glucose Tolerance by Liver-Specific Inhibition of SH2 Domain–Containing Inositol Phosphatase 2 (SHIP2) in Diabetic KKAy Mice

Author Correction: Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

Abstract LB003: BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

89 Zr-immuno-PET using the anti-LAG-3 tracer [ 89 Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

Inhibition of SH2-domain containing inositol phosphatase 2 (SHIP2) in insulin producing INS1E cells improves insulin signal transduction and induces proliferation

Phorbol ester-induced activation of mitogen-activated protein kinase/extracellular-signal-regulated kinase kinase and extracellular-signal-regulated protein kinase decreases glucose-6-phosphatase gene expression

Fingerprints of hSGLT5 sugar and cation selectivity

Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes

Normalization of Prandial Blood Glucose and Improvement of Glucose Tolerance by Liver-Specific Inhibition of SH2 Domain-Containing Inositol Phosphatase 2 (SHIP2) in Diabetic KKA^sup y^ Mice: SHIP2 Inhibition Causes Insulin-Mimetic Effects on Glycogen Metabolism, Gluconeogenesis, and Glycolysis

Tumour necrosis factor α decreases glucose-6-phosphatase gene expression by activation of nuclear factor κB

Suchergebnisse filtern